Bevacizumab in treatment of high-risk ovarian cancer-a cost-effectiveness analysis

Oncologist

Volumn 19, Issue 5, 2014, Pages 523-527

  Chan, John K ^a,b   Herzog, Thomas J ^c   Hu, Lilian ^a,d   Monk, Bradley J ^e   Kiet, Tuyen ^a   Blansit, Kevin ^a,b   Kapp, Daniel S ^f   Yu, Xinhua ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PALO ALTO MEDICAL FOUNDATION RESEARCH INSTITUTE   (United States)

^c Columbia University School of Medicine ^*  (United States)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^e CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MEMPHIS   (United States)

Author keywords

Bevacizumab; Cost effectiveness analysis; Markov chain; Ovarian cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER RISK; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; DRUG UTILIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; ECONOMICS; HEALTH CARE COST; MIDDLE AGED; MORTALITY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; QUALITY OF LIFE; STATISTICAL MODEL;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HEALTH CARE COSTS; HUMANS; MIDDLE AGED; MODELS, ECONOMIC; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; QUALITY OF LIFE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84900000768     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0322     Document Type: Article

References (26)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Presta LG, Chen H, O'Connor SJ et al. Humaniza-tion of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
3. Burger RA, Sill MW, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2007;25:5165-5171.
4. Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-5186.
5. Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-2483.
6. Perren TJ, Swart AM, Pfisterer J et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-2496.
7. MacLucas N. Roche's Avastin Wins EU Approval for Ovarian Cancer Treatment. Available at http://online.wsj.com/article/BT-CO-20111223-700271.html. Accessed December 23, 2011.
8. Pujade-Lauraine E, Hilpert F, Weber B et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012;30(suppl):LBA5002a.
9. Aghajanian C, Blank SV, Goff BA et al. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039-2045.
10. Elkin EB, Bach PB. Cancer's next frontier: Addressing high and increasing costs. JAMA 2010; 303:1086-1087.
11. Cohn DE, Kim KH, Resnick KE et al. At what cost does a potential survival advantageof bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011;29:1247-1251.
12. McGuire W, Neugut AI, Arikian S et al. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J Clin Oncol 1997;15:640-645.
13. Elit LM, Gafni A, Levine MN. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: An Ontario perspective. J Clin Oncol 1997;15:632-639.
14. Berger K, Fischer T, Szucs TD. Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective. Eur J Cancer 1998;34:1894-1901.
15. Bristow RE, Santillan A, Salani R et al. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for stage III ovarian cancer: A cost-effectiveness analysis. Gynecol Oncol 2007;106:476-481.
16. Havrilesky LJ, Secord AA, Darcy KM et al. Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: A Gynecologic On-cologyGroup study. J Clin Oncol 2008;26:4144-4150.
17. Rocconi RP, Case AS, Straughn J M Jr. et al. Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis. Cancer 2006;107:536-543.
18. Dalton HJ, Yu X, Hu L et al. An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer. Gynecol Oncol 2012;124:199-204.
19. Howlader NNA, Krapcho M, Garshell J et al. SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute, 2013.
20. Ubel PA, Hirth RA, Chernew ME et al. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003;163:1637-1641.
21. Montero AJ, Avancha K, Gluck S et al. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. Breast Cancer Res Treat 2012;132:747-751.
22. Phillips KA, Veenstra DL, Ramsey SD et al. Genetic testing and pharmacogenomics: Issues for determining the impact to healthcare delivery and costs. Am J Manag Care 2004;10:425-432.
23. Phillips KA, Marshall DA, Haas JS et al. Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer 2009;115:5166-5174.
24. Braithwaite RS, Meltzer DO, King JT Jr. et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008;46:349-356.
25. Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan. Clin Ther 2007;29:2256-2267.
26. Klein R, Muehlenbein C, Liepa AM et al. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2009;4:1404-1414.